Intervacc AB (IVACC) AI Stock Analysis

• Market Cap: kr314.23M
• Dividend Yield: N/A
• Average Volume (3M): 373.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 127.13%
• EPS Growth: 56.91%
• Country: SE
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 340,813,200
• 10 Day Avg. Volume: 453,808
• 30 Day Avg. Volume: 373,337
• PEG Ratio: 0.03
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 7.49
• P/FCF Ratio: -1.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): kr26.00M

• Rating: 40 Neutral
• Price Target: kr1.00 ▼(-5.66% Downside)

Intervacc AB's overall stock score is primarily impacted by its financial performance, which shows robust revenue growth but significant profitability and cash flow issues. The technical analysis indicates a bearish trend, and the valuation is weak due to the negative P/E ratio and lack of dividend yield. These factors collectively contribute to a low overall score.

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (IVACC) is a biotechnology company focused on developing innovative vaccines for companion animals and livestock. Operating primarily in the veterinary sector, IVACC's core products include vaccines aimed at preventing infectious diseases in animals, enhancing animal health, and supporting animal welfare. The company leverages its proprietary technology platforms to create effective immunization solutions that address unmet needs in the market.

How the Company Makes Money

Intervacc AB generates revenue through the development and commercialization of its vaccine products. The company typically earns income by selling its vaccines directly to veterinary clinics and animal health distributors, as well as through partnerships with larger pharmaceutical companies that may license its vaccine technologies. Additionally, IVACC may receive funding from research grants and collaborations aimed at advancing its vaccine research and development projects. Significant partnerships with industry leaders can also enhance its market presence and contribute to revenue growth through shared resources and joint marketing efforts.

Intervacc AB Financial Statement Overview

Summary

Intervacc AB demonstrates strong revenue growth but faces significant profitability and cash flow challenges. The company's low leverage provides financial stability, yet negative margins and returns indicate operational inefficiencies and cost management issues.

Income Statement

Intervacc AB shows a significant revenue growth rate of 30.62% TTM, indicating strong top-line expansion. However, the company struggles with negative margins across the board, including a gross profit margin of -5.45% and a net profit margin of -390.34% TTM, reflecting challenges in cost management and profitability. The EBIT and EBITDA margins are also deeply negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet is relatively stable with a very low debt-to-equity ratio of 0.00027 TTM, indicating minimal leverage and financial risk. However, the return on equity is negative at -28.20% TTM, highlighting poor returns for shareholders. The equity ratio is not explicitly calculated but the low leverage suggests a strong equity position relative to assets.

Cash Flow

Cash flow analysis reveals a modest improvement in free cash flow growth at 9.80% TTM, but the company still faces negative operating cash flow and free cash flow. The operating cash flow to net income ratio is -1.43 TTM, indicating cash flow challenges relative to earnings. The free cash flow to net income ratio is slightly positive at 1.01, suggesting some alignment between cash flow and net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.24M	11.79M	8.02M	9.68M	5.24M	4.78M
Gross Profit	-995.00K	-3.53M	-13.81M	3.37M	6.25M	4.64M
EBITDA	-54.66M	-58.75M	-68.98M	-57.73M	-23.15M	-19.39M
Net Income	-71.21M	-75.52M	-102.85M	-64.16M	-29.38M	-25.60M
Balance Sheet
Total Assets	362.24M	187.32M	259.61M	265.04M	329.39M	355.28M
Cash, Cash Equivalents and Short-Term Investments	202.05M	34.40M	88.34M	45.70M	115.71M	164.25M
Total Debt	88.00K	145.00K	181.00K	322.00K	433.00K	383.00K
Total Liabilities	37.43M	24.99M	21.68M	14.88M	21.14M	17.67M
Stockholders Equity	324.81M	162.33M	237.93M	250.16M	308.25M	337.61M
Cash Flow
Free Cash Flow	-54.01M	-53.90M	-47.94M	-75.92M	-48.67M	-31.50M
Operating Cash Flow	-53.36M	-53.20M	-45.83M	-69.79M	-25.46M	-20.08M
Investing Cash Flow	-646.00K	-706.00K	-2.11M	-6.13M	-23.13M	-11.27M
Financing Cash Flow	193.41M	-36.00K	90.58M	5.91M	50.00K	143.06M

Intervacc AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Negative. The current price of 1.06 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 1.00, and above the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.29 is Neutral, neither overbought nor oversold. The STOCH value of 24.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	48 Neutral	€217.39M	1.17	-16.90%	―	4.64%	―
ELIC	47 Neutral	kr261.61M	―	―	―	―	53.48%
IMMU	47 Neutral	kr259.64M	―	-16.51%	―	―	31.37%
ACE	43 Neutral	€390.59M	-2.68	-79.60%	―	―	31.62%
IVACC	40 Neutral	kr314.23M	―	-25.66%	―	127.13%	56.91%
IRLAB.A	38 Underperform	€204.70M	-1.53	-199.86%	―	69.03%	23.10%